Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2544062 | Journal of the American Pharmacists Association | 2008 | 8 Pages |
Abstract
These findings serve as a benchmark for lipid and blood glucose monitoring among patients who switch SGA therapy. Veterans' metabolic dysregulation was more likely to be monitored after SGA switch for those receiving pharmacologic treatment for metabolic dysregulation, monitored before the switch, and aged 50 years or older. Implementation of monitoring guidelines in daily practice is emphasized to ensure that individuals living with schizophrenia-related disorders and taking SGAs achieve optimal physical health.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Chienning (Doctoral Candidate), L. (Research Health Scientist, Professor), Michael A. (Assistant Chief), Patrick M. (Doctoral Candidate), Joel R. (Student Pharmacist), Farzad (Student Pharmacist),